利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.022 秒)

    ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND METHODS OF USE
    4.
    发明申请
    ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND METHODS OF USE 有权

    公开(公告)号：US20220119509A1

    公开(公告)日：2022-04-21

    申请号：US17491656

    申请日：2021-10-01

    申请人： argenx BVBA

    发明人： Christophe BLANCHETOT ,  Hans DE HAARD

    IPC分类号： C07K16/18

    摘要： Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.

    ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND METHODS OF USE
    6.
    发明申请
    ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2B AND METHODS OF USE 审中-公开

    公开(公告)号：US20200239554A1

    公开(公告)日：2020-07-30

    申请号：US16714264

    申请日：2019-12-13

    申请人： argenx BVBA

    发明人： Christophe Blanchetot ,  Hans de Haard

    IPC分类号： C07K16/18

    摘要： Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.

    ASYMMETRIC MULTISPECIFIC ANTIBODIES
    7.
    发明申请
    ASYMMETRIC MULTISPECIFIC ANTIBODIES 审中-公开

    公开(公告)号：US20200157248A1

    公开(公告)日：2020-05-21

    申请号：US16599883

    申请日：2019-10-11

    申请人： argenx BVBA

    发明人： Christophe Frederic Jerome BLANCHETOT ,  Johannes Joseph Wilhelmus DE HAARD

    IPC分类号： C07K16/46 ,  C07K16/42 ,  C07K1/22

    摘要： The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.

    METHOD OF PREPARING pH-DEPENDENT ANTIBODIES
    9.
    发明申请
    METHOD OF PREPARING pH-DEPENDENT ANTIBODIES 有权

    公开(公告)号：US20220177555A1

    公开(公告)日：2022-06-09

    申请号：US16606656

    申请日：2018-05-10

    申请人： argenx BVBA

    发明人： Christophe BLANCHETOT ,  Erik HOFMAN ,  Johannes DE HAARD ,  Jacobus Cornelis RASSER

    IPC分类号： C07K16/18

    摘要： Methods for preparing engineered antibodies exhibiting improved pH-dependent antigen binding are disclosed. The methods are based on introduction of histidine residues at a subset of defined amino acid positions within the antibody CDRs. The set of amino acid positions selected for histidine substitution is derived from a heat-map of histidine occurrence within the CDRs of functional antibodies from a natural antibody repertoire. The methods provide a simpler and less time-consuming approach to the identification of pH-dependent antibody variants.

    Antibodies that specifically bind to human complement factor C2b
    10.
    发明授权
    Antibodies that specifically bind to human complement factor C2b 有权

    公开(公告)号：US11161900B2

    公开(公告)日：2021-11-02

    申请号：US16714264

    申请日：2019-12-13

    申请人： argenx BVBA

    发明人： Christophe Blanchetot ,  Hans de Haard

    IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K39/00

    摘要： Provided are antibodies and antigen-binding fragments thereof that bind specifically to human complement factor C2 and are capable of inhibiting activation of the classical and lectin pathways of the complement system. The antibodies and antigen-binding fragment exhibit improved manufacturability, pharmacokinetics, and antigen sweeping. Also provided are pharmaceutical compositions comprising the antibodies and antigen-binding fragments, nucleic acids and vectors encoding the antibodies and antigen-binding fragments, host cells comprising the nucleic acids or vectors, and methods of making and using the antibodies and antigen-binding fragments. The antibodies and antigen-binding fragments can be used to inhibit the classical pathway of complement activation in a subject, e.g., a human. The antibodies and antigen-binding fragments can also be used to inhibit the lectin pathway of complement activation in a subject, e.g., a human.